Dan Appiah

Poolbeg Pharma has disclosed selected data from its human volunteer LPS challenge trial (EudraCT N0: 2022-001458-48) with its lead molecule POLB 001, following its initial announcement of the study's success in January.

Poolbeg Pharma has disclosed selected data from its human volunteer LPS challenge trial (EudraCT N0: 2022-001458-48) with its lead molecule POLB 001, following its initial announcement of the study's success in January.

Shield Therapeutics issued a February trading statement showing excellent US H122 vs H222 sales growth of 97% and confirmed a successful funding round of $31.7mln plus the $5mln Viatris deal fee.

Graphene Manufacturing Group (GMG) has a proprietary manufacturing process for producing high-quality graphene at scale from natural gas(methane). Innovative electrode technology enables GMG to modify its pure graphene to make advanced graphene + aluminium (G+AL) batteries. G+AL batteries are not yet commercial, but as the remaining technical and scale-up challenges are resolved, G+AL could have a massive market opportunity given its core technical advantages over dominant lithium technologies.

Tiziana's lead product is foralumab, a fully human antibody. The lead indication for intranasal foralumab is non-active secondary progressive multiple sclerosis (SPMS). The first two enrolled patients in the ongoing expanded access study showed encouraging responses. With planned completion of the necessary preclinical studies in Q123, we anticipate an IND filing by mid-2023 and a Phase 2 trial starting from Q323.

OCT has submitted an application to the UK regulator MHRA to gain approval for clinical studies. OCT's management expects this to complete during January. The lead contractor will deliver formulated oral 201 for clinical use around mid Q1. The Phase 1 volunteer study, run by a CRO, might then start by late March 2023. The Phase 1 should be fast to run and initial data might be available from mid-2023.

Creo Medical has issued a trading update showing increased licensing and core Creo revenues with steady Consumable sales. Creo, by steadily training more doctors to use its products, expects to see rapidly increasing sales of its dual-energy endoscopy tool: Speedboat.

Numinus Wellness Inc now has an extensive network of 12 clinics in the US and Canada delivering mental health wellness services through safe, evidencebased psychedelic-assisted therapies. The acquisition of Novamind in June 2022 has given Numinus a substantial base in the US by adding seven clinics in Utah and Arizona plus two laboratory research facilities.

In a trading update (12 December 2022), management indicates that their lead product OCT461201, an oral product to relieve peripheral nerve pain caused by cancer chemotherapy, will enter the clinical phase from January 2023.

Shield Therapeutics has signed a marketing partnership for Accrufer in the US and has simultaneously secured its funding position via a combined up to $33.5mln equity and debt fundraising.